Innovative Technology Attracts Investments, But Not Innovative Capital Structures, VC Says | GenomeWeb

“We like innovative technology, but not innovative capital structures,” Michael Lytton, general manager of Oxford Bioscience Partners, says when giving advice to early-stage companies seeking growth capital from venture capitalists.

Lytton recently spoke at Chips to Hits, a key microarray industry conference and his advice was targeted to those who are seeking funding for early-stage companies that engage in drug discovery.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.